GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Christian Debono joins VCFC as Chief Commercial Officer
'After 27 incredible years with HSBC, it’s time for a new chapter,' he said.
€6.9m subsea cable deal ‘the foundation for what we want to build in Cyprus’ – BMIT CEO
CEO Christian Sammut said BMIT ‘set out to broaden what the company is built on.’
Ruth Moisel appointed BridgeLink COO
'There is nothing quite like the energy of building something from the ground up', she said.
CEO says Computime ‘sharpening strategic direction’ and ‘reviewing leadership structure’
This, he said, will involve changes to certain leadership roles, the creation of new leadership positions.
